A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT06227975
- Locations
- 🇺🇸
Local Institution - 0001, Madison, Wisconsin, United States
A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT06170723
- Locations
- 🇺🇸
Local Institution - 0001, Tempe, Arizona, United States
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 156
- Registration Number
- NCT06163898
- Locations
- 🇺🇸
Local Institution - 0035, New Haven, Connecticut, United States
🇺🇸Local Institution - 0018, New York, New York, United States
🇺🇸Local Institution - 0033, Birmingham, Alabama, United States
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 618
- Registration Number
- NCT06045806
- Locations
- 🇺🇸
Local Institution - 0147, Columbus, Ohio, United States
🇺🇸Local Institution - 0102, Boston, Massachusetts, United States
🇩🇪Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 810
- Registration Number
- NCT05519085
- Locations
- 🇺🇸
Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT05214768
- Locations
- 🇯🇵
Local Institution - 002, Osaka, Japan
🇯🇵Local Institution - 022, Himeji-shi, Hyogo, Japan
🇯🇵Local Institution - 009, Nishinomiya, Hyogo, Japan
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT05175352
- Locations
- 🇺🇸
Local Institution - 021, Plantation, Florida, United States
🇺🇸Local Institution - 012, Columbus, Ohio, United States
🇺🇸Local Institution - 001, Los Angeles, California, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 84
- Registration Number
- NCT05099822
- Locations
- 🇧🇪
Local Institution - 001, Leuven, Vlaams Brabant, Belgium
Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT05065541
- Locations
- 🇧🇪
Local Institution - 001, Leuven, Vlaams Brabant, Belgium
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 63
- Registration Number
- NCT05028634
- Locations
- 🇺🇸
Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania, United States
🇺🇸Asheville Neurology Specialists PA, Asheville, North Carolina, United States
🇺🇸University of Florida Health, Gainesville, Florida, United States